News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Panacea Pharmaceuticals, Inc. Announces Appointment of Chief Patent Counsel (Business Wire)Panacea Pharmaceuticals, Inc. is pleased to announce the appointment of Mary E. Gormley, M.S., J.D. as Chief Patent Counsel for the Company.- Jan 03 12:12 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010103/md_panacea.html

Posted on: 01/03/2001

"Yahoo - Panacea Pharmaceuticals, Inc. Announces Appointment of Chief Patent Counsel"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
^DJI
^IXIC
^SPC
^IIX
^PSE
10591.66
2278.04
1276.90
243.60
756.49
-54.49
-13.82
-6.37
-2.33
-10.68
delayed 20 mins - disclaimer
Wednesday January 3, 12:12 pm Eastern Time

Press Release

Panacea Pharmaceuticals, Inc. Announces Appointment of Chief Patent Counsel

ROCKVILLE, Md.--(BW HealthWire)--January 3, 2001--Panacea Pharmaceuticals, Inc. is pleased to announce the appointment of Mary E. Gormley, M.S., J.D. as Chief Patent Counsel for the Company.

Ms. Gormley will be directing all company-wide intellectual property issues, including coordinating the Company's current activities with Brobeck, Phleger, & Harrison LLP in Washington, D.C., Shanks & Herbert LLP in Alexandria, Virginia, and Ropes & Gray in Boston, Massachusetts.

Ms. Gormley spent the last seven years as Senior Patent Counsel for Akzo Nobel (NASDAQ: AKZOY - news), an international company that serves customers throughout the world with pharmaceuticals, coatings, and chemicals.

At Akzo, Ms. Gormley was responsible for preparing and prosecuting domestic and foreign-based patents for several of Akzo's pharmaceutical business units, including Organon (pharmaceuticals), Intervet (veterinary vaccines and diagnostics), Organon Teknika (immunodiagnostics) and Advanced BioScience Laboratories (amplification and diagnostics).

She also participated in patent strategy development, the appeals and interference practice, third party infringement and freedom-to-use issues, and negotiating and preparing various intellectual property contracts.

Prior to that, Ms. Gormley held the position of Associate Patent Attorney for Armstrong, Westerman, et al LLP and Oliff and Berridge PLC, two Washington D.C. area law firms. She also served as a Patent Examiner for the United States Patent and Trademark Office, where she examined biotechnology-based patent applications.

Ms. Gormley spent six years as a researcher, mainly at the National Institute of Mental Health of the National Institutes of Health. She studied mitochondrial genetics as well as protein polymorphisms as markers of central nervous system diseases through the use of state-of-the-art proteomic techniques, with an emphasis on aging in humans.

Ms. Gormley received a B.S. in Microbiology from the University of Maryland, received a M.S. in Genetics and passed Ph.D. comprehensives from The George Washington University in Washington, D.C., and received her J.D. from the University of Maryland in Baltimore.

The Company is currently preparing several patent applications for discoveries resulting from in-house research and development efforts. "We welcome this timely addition of Mary to Panacea's management team," stated Kasra Ghanbari, Chief Operating Officer of the Company. "Her broad range of experience and expertise are well suited to effectively manage the Company's growing intellectual property portfolio."

Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system and cancer such as Alzheimer's disease, brain tumors, transmissible spongiform encephalopathies, and Lewy body diseases such as Parkinson's disease.

Changes in disease-relevant proteins by altered expression, post-translational modification, and functional variation are utilized to develop diagnostic tests and therapeutic agents.

More information is available at www.PanaceaPharma.com, a web site developed by eiCommunications.com, Inc. (www.eiCommunications.com), which offers written communications and web site promotion solutions for the Information Age.


Contact:
     Panacea Pharmaceuticals, Inc.
     Kasra Ghanbari
     Phone: 240/453-6295, Fax: 240/465-0450
     KGhanbari@PanaceaPharma.com

Email this story - Most-emailed articles - Most-viewed articles


Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved.Privacy Policy - Terms of Service

Copyright 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740